Chongqing Dongze Medicine Technology Development

Chongqing Dongze Medicine Technology Development is a pharmaceutical research and development company based in Chongqing, China, specializing in treatments for central nervous system disorders. The company is primarily focused on the clinical development of L-oxiracetam (S-oxiracetam), a nootropic small molecule designed to improve memory and cognitive function. Its lead candidate, L-oxiracetam injection, has advanced into Phase III clinical trials in China for patients suffering from cognitive impairment due to craniocerebral injuries. Chongqing Dongze collaborates with other domestic pharmaceutical entities, including Nanjing YOKO Pharmaceutical, to progress its pipeline of neurological therapies. The company's work centers on modulating glutamate receptors to address significant unmet needs in brain injury and stroke recovery.